Hippocampus and basal forebrain volumes modulate effects of anticholinergic treatment on delayed recall in healthy older adults  by Teipel, Stefan J. et al.
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 216-219Hippocampus and basal forebrain volumes modulate effects
of anticholinergic treatment on delayed recall in healthy older adultsStefan J. Teipela,b,*, Davide Brunoc, Michel J. Grothea, Jay Nierenbergd,e, Nunzio Pomarad,e
aGerman Center for Neurodegenerative Diseases (DZNE) – Rostock/Greifswald, Rostock, Germany
bDepartment of Psychosomatic Medicine, University of Rostock, Rostock, Germany
cDepartment of Psychology, Liverpool Hope University, Liverpool, UK
dGeriatric Psychiatry Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA
eDepartment of Psychiatry, School of Medicine, New York University, New York City, NY, USAAbstract Introduction: Volumes of hippocampus and cholinergic basal forebrain are associated with delayed*Corresponding a
494-9472.
E-mail address: st
http://dx.doi.org/10.10
2352-8729/ 2015 T
license (http://creativerecall performance and may modulate the effect of a muscarinic receptor antagonist on delayed recall
in healthy volunteers.
Methods: We studied 15 older adults before and after the oral administration of a single dose of 1 or
2 mg of the preferential M1 muscarinic receptor antagonist trihexyphenidyl (Artane) or placebo in
a double-blind randomized cross-over design. Hippocampus and basal forebrain volumes were
measured using magnetic resonance imaging.
Results: We found a significant interaction between treatment and hippocampus volume and a trend
level effect between treatment and anterior basal forebrain volume on task performance, with an
attenuation of the association between volume size and performance with trihexyphenidyl.
Discussion: These findings suggest a reduction of delayed recall performance with increasing doses
of the muscarinic antagonist that is related to an uncoupling of the association of task performance
with cholinergic basal forebrain and hippocampus volumes.
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Administration of trihexyphenidyl hydrochloride
(Artane) and other muscarinic receptor antagonists has
been reported to decrease delayed recall in healthy volun-
teers [1–3]. These findings are consistent with cholinergic
transmission playing a key role in attention and memory
tasks that require effort and concentration [4]. The main
cholinergic input to the human cerebral cortex arises from
the basal forebrain cholinergic nuclei [5]. The hippocampusuthor. Tel.: 149-381-494-9470; Fax: 149-381-
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).is involved in the coherent representation of a memory, a
requirement for successful retrieval [6]. The main cholin-
ergic input to the hippocampus arises from the most anterior
subnuclei of the cholinergic basal forebrain [7], termed Ch1
and Ch2 according to Mesulam’s nomenclature [8].
In this study, we examined whether the volumes of the
anterior basal forebrain and hippocampus, as measured
from structural magnetic resonance imaging (MRI) scans,
modulate the effect of anticholinergic treatment with trihex-
yphenidyl on delayed recall performance in a group of 15
cognitively and physically healthy older adults. We expected
that a higher volume would be associated with a higher de-
layed recall performance and that this association would
be reduced with higher doses of trihexyphenidyl.imer’s Association. This is an open access article under the CC BY-NC-ND
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The study included 15 healthy elderly individuals (eight
women), mean age was 66.9 (standard deviation [SD] 3.7)
years, ranging between 62 and 74 years, and mean education
was 16.7 (SD 2.3) years. Individuals did not take medica-
tions known to affect cognitive functioning, such as neuro-
leptics or antidepressants, at least 2 weeks before
beginning the study and had a negative urine toxicology
screen. Further details of recruitment have been described
before [9]. All subjects were only examined if they gave
their written informed consent. The study has been carried
out in accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki).2.1. Neuropsychological testing and study design
Participants were recruited as part of a study on the ef-
fects of APOE variants in response to trihexyphenidyl [9].
Delayed recall (after 15 minutes) was tested using the
Buschke Selective Reminding Test [10], administered
before and 1, 2.5, and 5 hours after drug/placebo administra-
tion. Each subject participated in the 3-week, double-blind,
randomized, placebo-controlled study, with sessions taking
place 1 week apart: treatment conditions were placebo,
1.0 mg, and 2.0 mg of trihexyphenidyl. To exclude training
effects within and across treatment sessions, 12 parallel
word lists were used, in a randomized rotational basis across
sessions. The same list was used across subjects in each of
the 12 assessment periods (treatment (3) X test time (4)).2.2. MRI data acquisition and analysis
The acquisition was performed on a 1.5 T Siemens Vision
system (Erlangen, Germany) at the Nathan S. Kline Institute
for Psychiatric Research, NY, USA. Images were acquired us-
ing a sagittal magnetization prepared rapid gradient-echo
sequence (repetition time/echo time 5 11.4/11.9 ms, 1 exci-
tation, matrix 5 256 ! 256, field of view 5 307 mm,
1.2 mm3 isotropic voxel, 172 slices, no gap).
MRI data processing followed procedures described pre-
viously for hippocampus [11] and basal forebrain [12]
volumetry, implemented in SPM8 and the VBM8-toolbox
in Matlab. Basal forebrain subregions [8] were determined
according to a map from an in cranio post-mortem MRI
scan and histology of a single individual’s brain, as previ-
ously described [12]. The total intracranial volume was
used in the statistical model to account for differences in
head size, and was calculated as the sum of the total
segmented gray matter, white matter, and cerebrospinal
fluid volumes in native space. We selected volumes of
left and right hippocampus and volumes of most anterior
basal forebrain nuclei, Ch1, and Ch2 according to Mesu-
lam’s nomenclature [8] that provide the main cholinergic
innervation of the hippocampus [7].2.3. Statistical analysis
We determined the effect of treatment on delayed recall
across subjects using a mixed effects model with subject-
related random effects, controlling for age and sex. For
time after drug intake (0–5 hours), we compared a linear
with a second order polynomial term. The model fit was
compared between the two nested models (first vs. second
order polynomial term for time) using Akaike’s information
criterion (AIC) [13].
To test for an interaction between volumes of basal fore-
brain and hippocampus, respectively, and the drug effect,
we selected the performance at the time of peak drug effect
(1–2.5 hours postingestion [14]); we also tested for main ef-
fects of volume and drug, and controlled for total intracranial
volume, sex, and age in all analyses. The significance of pa-
rameters was determined using t-statistics with degrees of
freedom determined according to the Satterthwaite approxi-
mation. For depiction of effects, we used the “effects” library
inR.We computed the fitted values and standard errors for de-
layed recall under the model for the interaction term of treat-
ment by (mean centered) volume with the values of the other
predictors being fixed at typical values, i.e., for an interval
scaled covariate at its mean, and for a factor at its proportional
distribution in the data, as described in [15].
Analyses were performed with R, version 3.1.1, including
the libraries “lme4” and “lmerTest,” available at http://cran.
r-project.org/web/packages.3. Results
In the basic model across all time points, we found a sig-
nificant linear effect of time on delayed recall performance
(t 5 24.6, df 5 162, P , .001). There was no significant
main effect of treatment (t 5 21.68, df 5 162, P 5 .09).
The second order polynomial model improved the fit over
the linear model (AIC 5 837.7 for the linear model and
AIC 5 813.1 for the polynomial model).
For hippocampus, considering the peak drug effect time
points only, we detected a significant volume by treatment
interaction (left and right hippocampus: t 5 22.1, df 5 72,
P 5 .04; Fig. 1) and a significant main effect of treatment
(t5 23.2, df5 72, P 5 .002). With anterior basal forebrain
volume, we observed a trend level significant interaction ef-
fect (t 5 21.8, df 5 72, P 5 .074; Fig. 2), and a significant
main effect of treatment (t 5 23.2, df 5 72, P 5 .002).
AIC of nested models indicated moderately improved fit for
the complex models compared with the basic model: basic
model AIC 5 423.4; full model with Ch1/2, AIC 5 421.3;
full model with left hippocampus, AIC 5 422.3; full model
with right hippocampus, AIC 5 422.2.4. Discussion
We found a decline in delayed recall performance in
response to the muscarinic antagonist trihexyphenidyl,
Fig. 1. Association of delayed recall performance with left hippocampus
volume at different levels of treatment. Treatment 1 mg5 1 mg trihexyphe-
nidyl. Treatment 2 mg 5 2 mg trihexyphenidyl.
Fig. 2. Association of delayed recall performance with anterior basal fore-
brain (Ch1/2) volume at different levels of treatment. For legend see Fig. 1.
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used a mixed effects model to take interindividual
variation in performance levels into account [16]. The time
activity curve of the drug was best modeled by a second or-
der polynomial consistent with the previously reported cen-
tral pharmacodynamics of trihexyphenidyl [14]. Under
placebo, hippocampal and anterior basal forebrain volumes
were positively associated with delayed recall performance.
The treatment-induced decline of performance was associ-
ated with a reduced or even reverse association between
regional volume and task performance with a higher dose
of the muscarinic receptor antagonist (Figs. 1 and 2). The
treatment-induced reductions of performance, compared
with placebo, were more pronounced at higher volumes.
This finding suggests the presence of a possible floor effect
for performance at smaller volumes whereby performance
levels only decrease slightly as a consequence of medication
because cholinergic blocking is less effective when the sys-
tem and its input areas in the hippocampus are already
impaired.
The numerically similar effects for the hippocampus
and the cholinergic system would indicate that cholinergic
input toward the hippocampus from the anterior basal fore-
brain (the main source of cholinergic projections to the hip-
pocampus [7]) only partially regulates hippocampus-relateddeterminants of delayed recall performance [17]. Because of
the limited number of participants in our sample, however,
we did not formally test for such a potential mediation effect.
Contrary to our observations, onemight have expected that
the effect of anticholinergic treatment on task performance
should be less pronounced with larger volumes rather than
with smaller volumes, if the former indicate a higher number
of neurons with viable M1 muscarinic receptors that could
compensate for a partial block of receptors. This assumption
would hold if the variation in volume size was not linked as a
state marker to performance but mainly represented a trait
marker of reserve capacity, and if the level of anticholinergic
effect was just above the threshold necessary to elicit func-
tional effects. Here, however, we examined a sample of older
adults where a low dose of the drug already induced signifi-
cant decline in performance. This suggests that variation in
cholinergic system integrity serves at least partially as a state
marker for functional performance, and at smaller volumes
the blockade of muscarinic receptors occurs in an already
impaired cholinergic system. To better resolve this question,
one would need to study the interaction between anticholin-
ergic treatment and hippocampus and basal forebrain volumes
in healthy young adults where variation in volume is expected
not to be rate limiting for task performance.
Increased atrophy of the cholinergic basal forebrain and
decline of cholinergic functioning over and above the effects
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and the development of dementia in neurodegenerative con-
ditions such as Alzheimer’s disease and Lewy body disor-
ders [11]. Controlled anticholinergic stress tests have been
proposed as prognostic markers for the development of de-
mentia in the elderly [18,19]. MRI-based measurements of
the structural integrity of the cholinergic basal forebrain
and its functionally relevant target areas may contribute
important neurobiological information to such pharmaco-
logical stress tests.
In summary, our findings, which should be replicated in
an independent sample, suggest that anticholinergic treat-
ment leads to a partial uncoupling of hippocampus and basal
forebrain atrophy from delayed recall task performance,
providing in vivo evidence that both structures functionally
subserve delayed recall mediated by cholinergic input to
the hippocampus.
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1. Systematic review: We reviewed the literature using
medical databases, such as PubMed, abstracts from
conferences, and cited work in review papers.
Many studies investigated behavioral effects of
cholinergic system dysfunction in rodents and mon-
keys, some studies also reported effects of long-
term and short-term anticholinergic treatment in
humans, but very few studies investigated the inter-
action between the integrity of key structures of the
cholinergic system and the effect of anticholinergic
treatment in humans.
2. Interpretation: Our findings suggest that cholinergic
system structural integrity modulates the effect of
anticholinergic treatment on delayed recall perfor-
mance in humans. These data provide in vivo evi-
dence on the structural underpinnings of
cholinergic function in the human brain.
3. Future directions: If confirmed in an independent
sample our data motivate the study of the potential
role of cholinergic system structural and functional
integrity to predict imminent cognitive decline in
cognitively healthy older people.References
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